洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2100049315】DBT in Hong Kong Mental Health Community Setting

基本信息
登记号

ChiCTR2100049315

试验状态

正在进行

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2021-07-30

临床申请受理号

/

靶点

/

适应症

Borderline Personality Disorder; Pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.)

试验通俗题目

DBT in Hong Kong Mental Health Community Setting

试验专业题目

The Effectiveness of Dialectical Behavior Therapy in a Mental Health Community Setting in Hong Kong

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

Dialectical Behavior Therapy (DBT) is an evidence-based treatment for individuals with symptoms of different psychiatric diagnoses (e.g., Cristea et al., 2017), particular those at risks for suicide or parasuicidal behavior (e.g., DeCou et al., 2019; Stanley et al., 2007) and those reporting emotion dysregulation (e.g., Kells et al., 2020). A transdiagnostic treatment that meets the needs of clinical populations at various risk levels can potentially mitigate the associated high cost to the health system as a whole. Considering the various components of DBT, establishment of a standard DBT program can be a multi-phasic project. Stand-alone DBT skills training groups have been found effective in reducing symptoms of mental health disorders (Valentine et al., 2014) and strengthening emotion regulation (Kells et al., 2020). Therefore, this study serves as a pilot and focuses on the effectiveness of skills training groups. Preliminary data collected will not only inform the projects subsequent phase(s) of expansion into a standard DBT program but also shed light on the implementation of DBT in an outpatient community setting in Hong Kong.

试验分类
请登录查看
试验类型

单臂

试验分期

Ⅲ期

随机化

N/A

盲法

N/A

试验项目经费来源

Lump sum grant

试验范围

/

目标入组人数

50

实际入组人数

/

第一例入组时间

2021-07-14

试验终止时间

2026-03-31

是否属于一致性

/

入选标准

- Aged 18 years or up; - Speak, read, and write Chinese; - Meet diagnostic criteria of Borderline Personality Disorder; OR show traits of pervasive dysregulation (e.g., behavioral, emotional, relational, etc.) with functional impairment in at least one domain (e.g., work, family, relationship, etc.); - Present treatment needs related to Stage 1 treatment targets as defined in DBT, such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Show elevation on screening measures such as the Borderline Symptom List 23 (BSL-23).;

排除标准

- Present with active psychosis without insight; - Demonstrate sub-average intelligence; - Decline to commit on Stage 1 treatment targets; that is, targets related to areas such as life-threatening concerns, therapy-interfering behaviors, quality-of-life-interfering behaviors; - Concurrently receive other psychological services.;

研究者信息
研究负责人姓名
请登录查看
试验机构

新生活精神康復協會

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

新生活精神康復協會的其他临床试验

香港新生活精神康復協會的其他临床试验

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

384,225
全球在研药物数
2,256
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,630亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看